Trial Profile
Randomised, Double-blind, parallel-group, active-comparator(venlafaxine extended release), fixed-dose study of LuAA21004 in Major Depressive Disorder in Asian countries
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Mar 2021
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary) ; Venlafaxine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms SOLUTION
- Sponsors Lundbeck A/S
- 06 Nov 2019 Results assessing treatment success of vortioxetine versus venlafaxine XR and cost-Effectiveness were presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 24 Sep 2019 Results (n=186) of pooled analysis of this and other two studies (NCT01676571 and NCT02386488) assessing pharmacokinetic analysis in Chinese and non-Chinese healthy subjects, published in the Advances in Therapy.
- 24 May 2017 Results assessing the overall performance priority the antidepressants: vortioxetine, agomelatine and venlafaxine XR in patients from two randomised trials (SOLUTION and REVIVE), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research